Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.52 |
| ▸ | SORD | Q00796 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534372 | 0.85 | BCHE (0.58) | BCHEACHEHTR3ATP53MAPT | |
| SCHEMBL3203133 | 0.84 | DRD2 (0.55) | BCHEACHEHTR3ATP53MAPT | |
| SCHEMBL10247572 | 0.79 | ACHE (0.65) | BCHEACHEHTR3ATP53MAPT | |
| SCHEMBL7841229 | 0.79 | BCHE (0.57) | BCHEACHEHTR3ATP53MAPT | |
| Hydrochloric Acid SCHEMBL7215392 | 0.78 | BCHE (0.56) | BCHEACHEHTR3ATP53MAPT | |
| SCHEMBL5309716 | 0.77 | BCHE (0.71) | BCHEACHEHTR3ATP53MAPT | |
| SCHEMBL2448672 | 0.77 | BACE1 (0.66) | BCHETP53RAB9ATRPC3KCNH2 | |
| SCHEMBL4436381 | 0.77 | BCHE (0.61) | BCHEACHEHTR3ATP53MAPT | |
| Hydrochloric Acid SCHEMBL1775985 | 0.77 | ACHE (0.61) | BCHEACHEHTR3ATP53MAPT | |
| Hydrochloric Acid SCHEMBL1775988 | 0.77 | ACHE (0.61) | BCHEACHEHTR3ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | BCHE 213/4885ACHE 120/4885HTR3A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.